NASDAQ:APLT Applied Therapeutics Q3 2025 Earnings Report $0.10 0.00 (0.00%) As of 07/31/2026 ProfileEarnings HistoryForecast Applied Therapeutics EPS ResultsActual EPS-$0.13Consensus EPS -$0.15Beat/MissBeat by +$0.02One Year Ago EPSN/AApplied Therapeutics Revenue ResultsActual Revenue$1.00 millionExpected Revenue$0.25 millionBeat/MissBeat by +$750.00 thousandYoY Revenue GrowthN/AApplied Therapeutics Announcement DetailsQuarterQ3 2025Date11/13/2025TimeBefore Market OpensConference Call DateThursday, November 13, 2025Conference Call Time7:00AM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) Applied Therapeutics Earnings HeadlinesApplied Therapeutics Stock Short Interest Report | NASDAQ:APLT | BenzingaJuly 12, 2026 | benzinga.comCycle Pharmaceuticals Completes Acquisition of Applied TherapeuticsFebruary 3, 2026 | businesswire.comThis AI fund sends investors payouts every ThursdayCrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names distributes income every single Thursday, with payouts reported as high as $1,051 a month. Chief Income Strategist Tim Plaehn breaks down the fund's real Thursday distribution history, how the income is generated, and how to buy it in any brokerage account.August 2 at 1:00 AM | Investors Alley (Ad)Cycle Pharmaceuticals Announces Extension of Applied Therapeutics Tender OfferJanuary 30, 2026 | businesswire.comApplied Therapeutics Shares Letter to Stockholders Recommending Tender of Shares Following Offer Expiration ExtensionJanuary 29, 2026 | globenewswire.comCycle Pharmaceuticals Announces Extension of Applied Therapeutics Tender OfferJanuary 29, 2026 | businesswire.comSee More Applied Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Applied Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Applied Therapeutics and other key companies, straight to your email. Email Address About Applied TherapeuticsApplied Therapeutics (NASDAQ:APLT), Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel small-molecule therapies for genetically defined diseases. Its research strategy centers on structure-based drug design and proprietary screening technologies aimed at correcting underlying metabolic dysfunction in disorders characterized by enzyme deficiencies and toxic metabolite accumulation. The company’s lead investigational candidate, AT-007, is an aldose reductase inhibitor engineered to cross the blood–brain barrier and is currently in clinical development for classic galactosemia. In addition to AT-007, Applied Therapeutics is advancing multiple programs targeting rare neurological and endocrine disorders, leveraging its platform to identify and optimize compounds that address high unmet medical needs in orphan and genetically defined patient populations. Founded and headquartered in New York City, Applied Therapeutics has established collaborative partnerships with academic research institutions and contract research organizations throughout North America and Europe to support its preclinical and clinical operations. The company is guided by a leadership team with extensive experience in drug discovery, clinical development and regulatory affairs, positioning Applied Therapeutics to advance its pipeline toward key clinical milestones and potential regulatory approval.View Applied Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Strategy's Structural Strength: Hidden in a $8 Billion IllusionMarketBeat Week in Review – 07/27- 07/31Chevron’s Strong Quarter Shows Why It Still Leads the Energy SectorAbbVie Quietly Solved Its Biggest Problem—Now What?Netflix's Big Sell-Off May Be Sending the Wrong SignalAmazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull CaseApple’s Record Quarter Could Not Outrun Its Guidance Problem Upcoming Earnings Booking (8/3/2026)Marriott International (8/3/2026)Diamondback Energy (8/3/2026)ONEOK (8/3/2026)Williams Companies (8/3/2026)Mitsubishi UFJ Financial Group (8/3/2026)Vertex Pharmaceuticals (8/3/2026)Palantir Technologies (8/3/2026)Spotify Technology (8/4/2026)SpaceX (8/4/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
